| scholarly article | Q13442814 |
| P50 | author | Qing Ma | Q42972374 |
| P2093 | author name string | Elinore F McCance-Katz | |
| David E Moody | |||
| Gene D Morse | |||
| Petrie M Rainey | |||
| Jennifer Baker | |||
| P2860 | cites work | Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection | Q44472471 |
| The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients | Q44540993 | ||
| Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine | Q44916978 | ||
| Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine | Q44924769 | ||
| Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir | Q44924772 | ||
| Diagnosis and management of hepatitis B virus and HIV coinfection. | Q45398740 | ||
| Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. | Q46790264 | ||
| Novel metabolites of buprenorphine detected in human liver microsomes and human urine | Q46871062 | ||
| Adherence, compliance, and HAART. | Q53966618 | ||
| Two New Rating Scales for Opiate Withdrawal | Q58291436 | ||
| Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography | Q68380573 | ||
| The metabolism and excretion of buprenorphine in humans | Q72592454 | ||
| Potential factors affecting adherence with HIV therapy | Q73916433 | ||
| Interaction of methadone with didanosine and stavudine | Q74254757 | ||
| Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262) | Q77142037 | ||
| The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry | Q83182002 | ||
| “Mini-mental state” | Q25938989 | ||
| The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz | Q28362277 | ||
| Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives | Q31808702 | ||
| Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone | Q33661055 | ||
| Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers | Q33837609 | ||
| Interactions between methadone and medications used to treat HIV infection: a review | Q34077001 | ||
| Viral hepatitis in HIV infection | Q34086980 | ||
| Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone | Q34348923 | ||
| Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir | Q34578756 | ||
| Clinical pharmacology of buprenorphine: ceiling effects at high doses | Q34662612 | ||
| Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users | Q34743004 | ||
| Office-based buprenorphine treatment for opioid-dependent patients | Q36069743 | ||
| Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents | Q36304438 | ||
| Treatment algorithm for chronic hepatitis B in HIV-infected patients | Q36341038 | ||
| Antiviral therapy of chronic hepatitis B. | Q36485082 | ||
| Future prospectives for the management of chronic hepatitis B. | Q36841719 | ||
| Review article: current antiviral therapy of chronic hepatitis B. | Q37157933 | ||
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 | ||
| Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market | Q37470350 | ||
| Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients | Q37598731 | ||
| Factors associated with exposure to hepatitis B virus in injection drug users | Q42680551 | ||
| Clinical pharmacokinetics of lamivudine | Q43755969 | ||
| Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir | Q43760231 | ||
| The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects | Q43904174 | ||
| A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women | Q44200491 | ||
| P433 | issue | 1 | |
| P921 | main subject | tenofovir | Q155954 |
| didanosine | Q422606 | ||
| lamivudine | Q422631 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 17-29 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | American Journal on Addictions | Q15762371 |
| P1476 | title | Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir | |
| P478 | volume | 19 |
| Q27692040 | A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice |
| Q35906594 | Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review |
| Q38435908 | Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. |
| Q37721776 | Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals |
| Q36105831 | Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study |
| Q35184385 | Gender differences in pharmacokinetics of maintenance dosed buprenorphine |
| Q46119171 | HIV and adolescents: focus on young key populations |
| Q37962449 | Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. |
| Q38093852 | Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine |
| Q37763615 | Methadone, buprenorphine, and street drug interactions with antiretroviral medications |
| Q34952233 | New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone |
| Q34851665 | Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy |
| Q93172741 | Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults |
| Q35131207 | Tailored combination prevention packages and PrEP for young key populations |
| Q35061983 | Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. |
Search more.